Sagent Pharmaceuticals, Inc. is a specialty and generic pharmaceutical company. The Company is a provider of pharmaceuticals to the hospital market, which it sells primarily throughout North America. It is focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market. It operates through two segments: Sagent US, consisting of the Company's operations in the United States and the Sagent (China) Pharmaceuticals Co. Ltd. (SCP) manufacturing facility, and Omega, which is focused on the Canadian and international markets. It offers a range of products across anti-infective, oncology and critical care indications in a range of presentations, including single and multi-dose vials, pre-filled ready-to-use syringes and premix bags. Its Sagent US product portfolio includes approximately 60 marketed products that it offers in over 180 presentations, and its Omega segment offers over 50 products.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
SymbolNASDAQ:SGNT
CUSIP78669210
Phone+1-847-9081604
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-0.72%
Return on Equity-0.81%
Return on Assets-0.59%
Miscellaneous
EmployeesN/A
Outstanding Shares33,090,000
Sagent Pharmaceuticals (NASDAQ:SGNT) Frequently Asked Questions
What is Sagent Pharmaceuticals' stock symbol?
Sagent Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGNT."
How were Sagent Pharmaceuticals' earnings last quarter?
Sagent Pharmaceuticals Inc (NASDAQ:SGNT) issued its quarterly earnings results on Tuesday, May, 3rd. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by $0.16. The firm had revenue of $67.30 million for the quarter, compared to analyst estimates of $74.30 million. Sagent Pharmaceuticals had a negative net margin of 0.72% and a negative return on equity of 0.81%. The firm's revenue for the quarter was down 17.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.04 earnings per share. View Sagent Pharmaceuticals' Earnings History.
Has Sagent Pharmaceuticals been receiving favorable news coverage?
Media coverage about SGNT stock has been trending somewhat positive on Tuesday, according to Accern Sentiment. Accern scores the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sagent Pharmaceuticals earned a news sentiment score of 0.17 on Accern's scale. They also assigned news stories about the company an impact score of 47.14 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
How do I buy shares of Sagent Pharmaceuticals?
Shares of SGNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sagent Pharmaceuticals' stock price today?
One share of SGNT stock can currently be purchased for approximately $21.76.
How can I contact Sagent Pharmaceuticals?
Sagent Pharmaceuticals' mailing address is 1901 N Roselle Rd Ste 700, SCHAUMBURG, IL 60195-3194, United States. The company can be reached via phone at +1-847-9081604.
MarketBeat Community Rating for Sagent Pharmaceuticals (SGNT)
MarketBeat's community ratings are surveys of what our community members think about Sagent Pharmaceuticals and other stocks. Vote "Outperform" if you believe SGNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
